VRTX

AI Research

Povetacicept IgA nephropathy Phase 3 -50% proteinuria → VRTX Truist raises to $525

Vertex Pharmaceuticals reported highly positive Phase 3 trial results for povetacicept in IgA nephropathy, showing a 50% reduction in proteinuria — a key marker of kidney disease progression — which exceeded analyst expectations and positions the drug as a potential best-in-class treatment for a large underserved patient population. Truist raised its price target to $525 in response to the data, and the broader analyst community now forecasts peak sales potential of $3-4 billion annually for the indication. Risks include competitive pressure from RemeGen and Chinook/Novartis in the IgA nephropathy space, and manufacturing scale-up timelines that could delay commercial launch.